摘要：Background/Aim. Autologous stem cell transplants (ASCTs) improve the rate of overall survival (OS) in patients with hematological malignancies such as multiple myeloma (MM) after induction chemotherapy, aggressive non-Hodgkin's lymphomas (NHL), and relapsed, chemotherapy- sensitive Hodgkin's lymphoma (HL). The study aim was to evaluate influence of applied CD34 cell quantity on clinical outcome, as well as early post-transplant and overall survival (OS) of HL and MM patients following ASCT. Methods. This study included a total of 210 patients (90 HL/120 MM) who underwent ASCT. Stem cell (SC) mobilization was accomplished by granulocyte-colony stimulating factor (G-CSF) 10?16 ?g/kg body mass (bm) following chemotherapy. For proven poor mobilizers, mobilization with G-CSF (16 ?g/kgbm) and Plerixafor (24 or 48 mg) was performed. To our best knowledge, it was the first usage of the Plerixafor in our country in the ASCT-setting. Harvesting was initiated merely at "cut-off-value" of CD34 cells ? 20 ? 106/L in peripheral blood with "target-dose" of CD34 cells ? 5 ? 106/kgbm in harvest. The CD34 cell count and viability was determined using flow cytometry. Results. The majority of HL patients (76.7%) were infused with > 5.0 ? 106/kgbm CD34 cells, while 68.3% of MM patients were treated by approximately 4.0?5.4 ? 106/kgbm CD34 dose, respectively. Beneficial response (complete/ partial remission) was achieved in 83.3% (HL) and 94.2% (MM) patients. Among parameters that influenced survival of HL patients with positive response to the therapy, multivariate analysis (pre-ASCT performance status, CD34 cell quantity applied, rapid hematopoietic, i.e. lymphocyte and platelet recovery) indicated that higher CD34 cell dose used, along with pre-ASCT performance status correlated with superior event-free survival (EFS) and OS following ASCT. In MM patients, multivariate analysis (renal impairment, infused CD34 cell quantity, early platelet recovery) indicated that the number of CD34 cells infused was the most important parameter that influenced both EFS and OS after ASCT. Conclusion. Data obtained in this study undoubtedly confirmed that CD34 cell dose applied is an independent factor that may contribute to superior clinical outcome and OS of HL and MM patients following ASCT.
